Valuation dashboard for Xencor, Inc. (XNCR) with P/E N/A, P/B 5.38, EV/EBITDA -18.21 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders.
Analysis Summary
Xencor, Inc. reported revenue of $125.6M in the most recent fiscal year, growing at a 5-year CAGR of 0.5%.
Trailing-twelve-month margins: gross margin 43.3%, operating margin -205.8%, net margin -155.6%.
At $29.99 (closing price, October 28, 2026), XNCR has negative trailing earnings (P/E not meaningful) and an ROE of -28.66%. Market capitalisation stands at $2.2B.
Balance sheet quality for XNCR: current ratio of 6.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 5.38 |
| EV / EBITDA | -18.21 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-6.47 |
| vs Current Price | -121.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| XNCR | Xencor, Inc. | $2.2B | 5.38 | -28.7% | |
| GMAB | Genmab A/S | $35.2B | 45.15 | 4.59 | 13.6% |
| CLDX | Celldex Therapeutics, Inc. | $2.3B | 3.32 | -52.4% | |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | 10.97 | 3.14 | 49.3% |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.3B | 30.83 | 6.64 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| MRNA | Moderna, Inc. | $85.5B | 12.54 | -39.2% |
Price
| Price | $29.99 (closing price, October 28, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -28.66% |
| Return on Invested Capital | -33.40% |
| Return on Assets | -22.53% |
| Gross Margin | 43.31% |
| Operating Margin | -205.84% |
| Net Margin | -155.59% |
Related companies: GMAB · CLDX · NRIX · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN
Explore sector: Healthcare · Biotechnology
More sections of XNCR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks